Results 211 to 220 of about 86,994 (313)

Effects of Ethanol and Opioid Receptor Antagonists Naltrexone and LY2444296 on the Organization of Cholesterol- and Sphingomyelin-Enriched Plasma Membrane Domains. [PDF]

ACS Chem Neurosci
Oasa S, Mak WH, Maddox AL, Lima C, Saftics A, Terenius L, Jovanović-Talisman T, Vukojević V.   +7 more
europepmc   +1 more source

Learning-Related Translocation of δ-Opioid Receptors on Ventral Striatal Cholinergic Interneurons Mediates Choice between Goal-Directed Actions

, 2013
Jesus Bertran‐Gonzalez, Vincent Laurent, Billy Chieng, MacDonald J. Christie, Bernard W. Balleine   +4 more
openalex   +2 more sources

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

µ-Opioid Receptor Control of Glutamate/GABA Coreleasing SUM and VTA Projections to the Dentate Gyrus. [PDF]

J Neurosci
Oleinichenko D.
europepmc   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Structure-guided design of partial agonists at an opioid receptor. [PDF]

Nat Commun
Varga BR, Bernhard SM, El Daibani A, Zaidi SA, Lam JH, Aguilar J, Appourchaux K, Nazarova AL, Kouvelis A, Shinouchi R, Hammond HR, Eans SO, Weinreb V, Margolis EB, Fay JF, Huang XP, Pradhan A, Katritch V, McLaughlin JP, Majumdar S, Che T.   +20 more
europepmc   +1 more source

Cholesterol reduction by methyl-β-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells

, 2006
Peng Huang, Wei Xu, Su-In Yoon, Chongguang Chen, Parkson Lee‐Gau Chong, Lee‐Yuan Liu‐Chen   +5 more
openalex   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Mu-opioid receptor activation potentiates excitatory transmission at the habenulo-peduncular synapse. [PDF]

Cell Rep
Singhal SM, Szlaga A, Chen YC, Conrad WS, Hnasko TS.   +4 more
europepmc   +1 more source

Influence of opioid receptors in the propofol-induced hypotension in humans

, 2015
Madalena Juliana da Silva Freitas
openalex   +1 more source